NCT06298084 - Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

June 30, 2029

Conditions

Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast CarcinomaAdvanced Breast Cancer

Interventions

DRUG

Patritumab deruxtecan

5.6 mg/kg every 21 days

DRUG

Olaparib

100 mg b.i.d PO days 8-14 every 21 days

Trial Locations (1)

RECRUITING

Gustave Roussy Institut, Villejuif